This website uses cookies to deliver to you the best experience possible on SITC CONNECT. By continuing to use this site, you are providing to us your consent to ensure you receive such an experience.View our privacy policy to learn more.

Regulatory Issues

Society for Immunotherapy of Cancer (SITC) leaders have prioritized the following areas of focus in addressing regulatory issues relating to the field of cancer immunotherapy:

Adverse Events Reporting

Clinical Trial Design/Endpoints

Combination Approaches

SITC has forged strategic relationships with government and regulatory entities from around the world to address key regulatory issues including formal liaison relationships with the U.S. Food and Drug Administration (FDA) and the National Cancer Institute/National Institutes of Health (NCI/NIH).

Toxicity Management Workshop

There is an urgent need among practicing oncologists and nurses for treatment algorithms that guide management of immunotherapy-related toxicities. Similarly, standardized templates for reporting adverse events in clinical trials are needed in order to facilitate monitoring and reporting of toxicities, an effort which is considered a high priority by the U.S. Food and Drug Administration.

To this end, SITC took the lead to convene a one-day Toxicity Management Workshop on Friday, March 31, 2017, in Washington, D.C. Click here to learn more about this event.